Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Bridgepoint delivers 'strong' FY performance

(Sharecast News) - Private investment firm Bridgepoint delivered a "strong" full-year performance on Thursday and said it was "well placed" for continued growth. Bridgepoint said standalone organic assets under management were up 7% at €41.0bn, while underlying pre-tax profits grew 12% to £134.0m, giving earnings per share of 14.9p, and underlying earnings were 7% higher at £149.0m. Management fees were up 10% at £265.0m and underlying fee-related earnings increased 28% to £95.0m.

The company added that its acquisition of ECP was expected to close in the second quarter, with fundraising for ECP V, which has a target of €4.0bn, was set to close in April. Including the recently acquired business, assets under management rose 62% year-on-year to €62.0bn.

Chief executive Raoul Hughes said: "2023 has been a very strong year for Bridgepoint with underlying profit growth of 12% year-on-year, on the back of robust investment returns, strong progress on fundraising and fund deployment, and good cost control. 2024 has started equally strongly with fundraising shortly to close for BE VII with commitments on target at €7.0bn.

As of 1010 GMT, Bridgepoint shares were up 0.23% at 262.0p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

Biome Technologies shares sink as Q1 sales drop 44%
(Sharecast News) - Shares in AIM-listed Biome Technologies plummeted by almost a third on Monday after the bioplastics and radio frequency technology business reported a poor start to the year with first-quarter sales dropping by 44%.
Entain reprices two term loans, revises interest cost outlook
(Sharecast News) - Betting and gambling giant Entain announced the successful repricing of two of its existing 'Term Loan B' loans on Monday, along with the pricing and allocation of fungible add-ons, in a bid to optimise its financial position.
Oxford Biomedica confident as it moves away from vaccine era
(Sharecast News) - Cell and gene therapy contract development and manufacturing organisation (CDMO) Oxford Biomedica reported stability in its core business on Monday, with a small increase in full-year core revenue for 2023, despite a 36% decrease in total revenue to £89.5m.
N Brown chairman Ron McMillan to retire
(Sharecast News) - N Brown said on Monday that chairman Ron McMillan will be retiring and stepping down from the board with effect from 30 April for personal reasons.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.